Overview
The goal of this clinical trial is to analyse the impact of a telematic assessment and monitoring protocol in people with cystic fibrosis, in order to identify exacerbations early, thus preventing loss of lung function and maintaining quality of life.
Participants will be assigned to one of 3 study groups:
Control group (CG-1): will receive their usual physiotherapy treatment; Treatment group (TG-2): will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment; Treatment and follow-up group (TGF-3): will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment, plus telematic control of exacerbations with feedback from the physiotherapist.
Eligibility
Inclusion Criteria:
- Diagnosed cystic fibrosis
- Family access to an internet-enabled device
- Camera and microphone
- Absence of exacerbations in the last 30 days
Exclusion Criteria:
- Patients with lung transplant or on the waiting list for lung transplantation
- Previous eye surgery (3 months)
- Hemothorax
- Active infection or inflammatory process
- Tumors
- Cognitive problems that make it impossible for them to use telematic devices.